SCHEMBL9984200

SCHEMBL9984200

Cc1ccc(S(=O)(=O)OC2=C(C(=O)c3ccc4ccccc4c3)N(C)S(=O)(=O)c3ccccc32)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.56
POLB P06746 3/20 0.56
ENPP2 Q13822 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
ALDH1A1 P00352 1/20 0.46
RECQL P46063 1/20 0.46
TP53 P04637 4/20 0.46
HSD11B1 P28845 2/20 0.45
GAA P10253 1/20 0.39
THRB P10828 1/20 0.39
KAT6A Q92794 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9984079 0.93 MAPT (0.51) MAPTPOLBENPP2SMN1; SMN2CYP3A4
SCHEMBL9983964 0.91 MAPT (0.46) MAPTPOLBENPP2SMN1; SMN2CYP3A4
SCHEMBL9983512 0.90 MAPT (0.45) MAPTPOLBENPP2SMN1; SMN2CYP3A4
SCHEMBL9983705 0.89 MAPT (0.43) MAPTPOLBENPP2SMN1; SMN2CYP3A4
SCHEMBL9984138 0.84 MAPT (0.78) MAPTPOLBSMN1; SMN2CYP3A4CYP2C9
SCHEMBL9983311 0.83 ENPP1 (0.43) MAPTPOLBENPP2SMN1; SMN2TDP1
SCHEMBL9984267 0.83 MAPT (0.80) MAPTPOLBSMN1; SMN2CYP3A4CYP2C9
SCHEMBL9983603 0.82 ENPP1 (0.42) MAPTPOLBENPP2SMN1; SMN2TDP1
SCHEMBL9983662 0.81 MAPT (0.55) MAPTPOLBSMN1; SMN2CYP3A4CYP2C9
SCHEMBL6796572 0.81 MAPT (0.52) MAPTPOLBSMN1; SMN2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187438-B2 Derivatives of benzothiazines, preparation thereof and application thereof as drugs PIERRE FABRE MEDICAMENT (FR) 2015-11-17 US claimed
EP-2403840-B1 DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS PF MEDICAMENT (FR) 2014-05-14 EP claimed
US-20110319326-A1 DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS PIERRE FABRE MEDICAMENT (FR) 2011-12-29 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319326-A1 DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS HSD11B1, CYP11B1, HSD17B11 MAPT 4086/4885POLB 2821/4885ENPP2 4438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.